BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

已收盘 06-05 16:00:00 EDT

108.73

+0.60

+0.55%

盘后107.50

-1.23-1.13%

19:52 EDT

最高108.93	最低107.21	成交量44.54万
今开107.30	昨收108.13	日振幅1.59%
总市值262.03亿	流通市值94.99亿	总股本2.41亿
成交额4,833万	换手率0.51%	流通股本8,736万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":108.73,"timestamp":1685995200000,"preClose":108.13,"halted":0,"volume":445413,"hourTrading":{"tag":"盘后","latestPrice":107.5,"preClose":108.73,"latestTime":"19:52 EDT","volume":7802,"amount":848285.58,"timestamp":1686009169728},"delay":0,"floatShares":87360815,"shares":240990499,"eps":27.5403,"marketStatus":"已收盘","marketStatusCode":5,"change":0.6,"latestTime":"06-05 16:00:00 EDT","open":107.3,"high":108.93,"low":107.21,"amount":48329216.867639996,"amplitude":0.015907,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":27.5403,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1686038400000},"adr":0,"listingDate":1570680000000,"adjPreClose":108.13,"adrRate":1,"preHourTrading":{"tag":"盘前","latestPrice":107.74,"preClose":108.13,"latestTime":"09:29 EDT","volume":2925,"amount":314985.3525,"timestamp":1685971770009},"postHourTrading":{"tag":"盘后","latestPrice":107.5,"preClose":108.73,"latestTime":"19:52 EDT","volume":7802,"amount":848285.58,"timestamp":1686009169728},"volumeRatio":0.689137},"requestUrl":"/m/hq/s/BNTX","defaultTab":"news","newsList":[{"id":"2340748110","title":"Biontech Se盘中异动 早盘快速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2340748110","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2340748110?lang=zh_CN&edition=full","pubTime":"2023-06-02 21:47","pubTimestamp":1685713658,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202306022147398066e372&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202306022147398066e372&s=b","is_publish_highlight":false},{"id":"2340571942","title":"新冠病毒再感染有哪些风险？","url":"https://stock-news.laohu8.com/highlight/detail?id=2340571942","media":"虎嗅","top":-1,"share":"https://www.laohu8.com/m/news/2340571942?lang=zh_CN&edition=full","pubTime":"2023-06-02 19:58","pubTimestamp":1685707116,"startTime":"0","endTime":"0","summary":"“从未有病毒被如此系统地研究过”","market":"hk","thumbnail":"https://img.huxiucdn.com/article/cover/202306/02/185643983092.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202306/02/185643983092.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/1629199.html","is_publish_highlight":false},{"id":"2337958908","title":"Biontech Se盘中异动 早盘快速跳水5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2337958908","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2337958908?lang=zh_CN&edition=full","pubTime":"2023-05-24 22:07","pubTimestamp":1684937272,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230524220752836439b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230524220752836439b4&s=b","is_publish_highlight":false},{"id":"2337964087","title":"Biontech Se盘中异动 临近午盘急速上涨5.07%报112.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2337964087","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2337964087?lang=zh_CN&edition=full","pubTime":"2023-05-23 23:43","pubTimestamp":1684856638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052323435884722919&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023052323435884722919&s=b","is_publish_highlight":false},{"id":"2334227658","title":"Biontech Se盘中异动 大幅跳水5.01%报102.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2334227658","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2334227658?lang=zh_CN&edition=full","pubTime":"2023-05-10 00:04","pubTimestamp":1683648262,"startTime":"0","endTime":"0","summary":"北京时间2023年05月10日00时04分，Biontech Se股票出现异动，股价快速跳水5.01%。Biontech Se股票所在的生物技术行业中，整体跌幅为0.20%。消息层面，截至00时04分，Biontech Se股票正面舆情新闻比例100%。财报显示，BioNTech一季度营收12.77亿欧元，同比降低79.7%，超出市场预期的10.7亿欧元；摊薄后每股收益为2.05欧元，超出市场预期的1.35欧元，上年同期为14.24欧元。BioNTech重申2023年新冠疫苗收入指引约为50亿欧元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305100004228064e96d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305100004228064e96d&s=b","is_publish_highlight":false},{"id":"2333878162","title":"BioNTech(BNTX.US)Q1业绩超预期 预期全年新冠疫苗销售收入为50亿欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2333878162","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2333878162?lang=zh_CN&edition=full","pubTime":"2023-05-08 19:30","pubTimestamp":1683545400,"startTime":"0","endTime":"0","summary":"财报显示，BioNTech一季度营收12.77亿欧元，同比降低79.7%，超出市场预期的10.7亿欧元；摊薄后每股收益为2.05欧元，超出市场预期的1.35欧元，上年同期为14.24欧元。BioNTech指出，一季度营收下滑的主要原因是在全球范围内供应和销售新冠疫苗的商业收入减少。截至2023年3月31日，BioNTech持有的现金和现金等价物以及证券投资分别为121.439亿欧元和6.719亿欧元。业绩指引BioNTech重申2023年新冠疫苗收入指引约为50亿欧元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/927466.html","is_publish_highlight":false},{"id":"2333821022","title":"BioNtech(BNTX)盘前涨6% Q1净利润5亿欧元 大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2333821022","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2333821022?lang=zh_CN&edition=full","pubTime":"2023-05-08 19:19","pubTimestamp":1683544750,"startTime":"0","endTime":"0","summary":"周一美股盘前，BioNtech(BNTX)公布2023年第一季度财务业绩。数据显示，该公司Q1营收12.77亿欧元，预期14.28亿欧元；净利润5亿欧元，预期2800万欧元。第一季度运营收入为6.544亿欧元，市场预计为2.318亿欧元。展望未来，仍预计本财年的资本支出为5亿欧元至6亿欧元。仍预计全年COVID-19疫苗收入约为50亿美元。截止发稿，BioNtech盘前涨6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230508191943844174a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230508191943844174a9&s=b","is_publish_highlight":false},{"id":"2333460378","title":"新冠突发公卫事件完结，但它仍是全球大流行病","url":"https://stock-news.laohu8.com/highlight/detail?id=2333460378","media":"虎嗅","top":-1,"share":"https://www.laohu8.com/m/news/2333460378?lang=zh_CN&edition=full","pubTime":"2023-05-06 21:49","pubTimestamp":1683380984,"startTime":"0","endTime":"0","summary":"过渡到新冠的长期管理","market":"sh","thumbnail":"https://img.huxiucdn.com/article/cover/202305/06/211353549943.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202305/06/211353549943.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/1450626.html","is_publish_highlight":false},{"id":"2333463676","title":"世卫宣布新冠公卫紧急状态结束，我们还需要担心吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2333463676","media":"虎嗅","top":-1,"share":"https://www.laohu8.com/m/news/2333463676?lang=zh_CN&edition=full","pubTime":"2023-05-06 16:28","pubTimestamp":1683361722,"startTime":"0","endTime":"0","summary":"“一切都没有发生，一切都已经发生”","market":"hk","thumbnail":"https://img.huxiucdn.com/article/cover/202305/06/153315726339.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202305/06/153315726339.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/1447779.html","is_publish_highlight":false},{"id":"2330364145","title":"圣诺医药-B(02257)：达冕生物的COVID-19疫苗RV-1730获得了美国FDA的新药研究申请批准，将作为加强疫苗进行一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2330364145","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2330364145?lang=zh_CN&edition=full","pubTime":"2023-04-27 22:06","pubTimestamp":1682604394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B 发布公告，集团非全资子公司RNAimmune宣布近日接到了美国食品和药物管理局对其新药研究申请的正式批准，公司即将启动其产品RV-1730作为新型冠状病毒加强疫苗候选的I期临床试验。临床试验将研究RV-1730在先前已接种了其他新型冠状病毒mRNA疫苗的人群中作为加强针预防新型冠状病毒感染的效果。受试者将接受RV-1730的三个剂量之一，剂量组分别有：。受试者将在接种后进行为期","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/922162.html","is_publish_highlight":false},{"id":"2328206245","title":"大流行之后，我们更想要室内清新空气了","url":"https://stock-news.laohu8.com/highlight/detail?id=2328206245","media":"虎嗅","top":-1,"share":"https://www.laohu8.com/m/news/2328206245?lang=zh_CN&edition=full","pubTime":"2023-04-19 16:40","pubTimestamp":1681893634,"startTime":"0","endTime":"0","summary":"二氧化碳让你昏昏欲睡，也让你更易感染","market":"us","thumbnail":"https://img.huxiucdn.com/article/cover/202304/19/161322062426.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202304/19/161322062426.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/1222345.html","is_publish_highlight":false},{"id":"2325350840","title":"舒泰神(300204.SZ)：参股公司InflaRx研发药物Gohibic(Vilobelimab)注射液用于治疗COVID-19获得FDA紧急使用授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2325350840","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2325350840?lang=zh_CN&edition=full","pubTime":"2023-04-05 16:45","pubTimestamp":1680684358,"startTime":"0","endTime":"0","summary":"InflaRx 成立于 2007 年，在德国耶拿和慕尼黑以及美国密歇根州安娜堡设有办事处和关联公司。根据 FDA 官网显示，FDA 已发布紧急使用授权，允许在接受有创机械通气或体外膜肺氧合后 48 小时内开始使用 Gohibic注射液治疗住院成人的 COVID-19。该治疗针对免疫系统的一部分，该部分被认为在导致 COVID-19 疾病进展的炎症中发挥作用。支持授权的临床试验表明，与安慰剂相比，在有创机械通气的危重型 COVID-19 患者中，Vilobelimab 治疗组的 28 天全因死亡率显著降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/906680.html","is_publish_highlight":false},{"id":"2323188081","title":"BioNTech(BNTX.US)盘前跌逾1% 遭大摩下调目标价至150美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2323188081","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2323188081?lang=zh_CN&edition=full","pubTime":"2023-03-31 16:55","pubTimestamp":1680252900,"startTime":"0","endTime":"0","summary":"格隆汇3月31日丨BioNTech盘前跌1.4%，报120.85美元。大摩分析师Matthew Harrison将BioNTech的目标价从216美元下调至150美元，并保持对该股的持股观望评级。BioNTech第四季度收入超过预期，但这“不是投资者关注的焦点”，因为管理层指引2023年新冠疫苗销售额约为50亿欧元，而共识预测为80亿欧元。大摩降低了对该公司新冠疫苗业务的中期收入，以考虑指引和欧盟合同的重新调整，并表示随着“新冠相关数字现在被重置”，2023年的重点可以转移到研发生产系统。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2023-03-31/doc-imynuhca4322661.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2023-03-31/doc-imynuhca4322661.shtml","is_publish_highlight":false},{"id":"2323608579","title":"Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2323608579","media":"GlobeNewswire","top":-1,"share":"https://www.laohu8.com/m/news/2323608579?lang=zh_CN&edition=full","pubTime":"2023-03-31 08:00","pubTimestamp":1680220800,"startTime":"0","endTime":"0","summary":"SHANGHAI, China, March  31, 2023  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2023/03/31/2638412/0/en/Junshi-Biosciences-Announces-2022-Full-Year-Financial-Results-and-Provides-Corporate-Updates.html","is_publish_highlight":false},{"id":"2323619407","title":"【券商聚焦】摩根士丹利分析师：下调BioNTech(BNTX)目标价至150美元 维持持股观望评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2323619407","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2323619407?lang=zh_CN&edition=full","pubTime":"2023-03-30 15:28","pubTimestamp":1680161301,"startTime":"0","endTime":"0","summary":"摩根士丹利(MS)分析师Matthew Harrison将BioNTech(BNTX)的目标价从216美元下调至150美元，并维持对该股的持股观望评级。Harrison表示，BioNTech第四季度收入超过预期，但这“不是投资者关注的焦点”，因为管理层指引2023年新冠疫苗销售额约为50亿欧元，而共识预测为80亿欧元。该分析师降低了对该公司新冠疫苗业务的中期收入，以考虑指引和欧盟合同的重新调整，并表示随着“新冠相关数字现在被重置”，2023年的重点可以转移到研发生产系统。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=4bb683404ddbb798c542563bae47f87d","is_publish_highlight":false},{"id":"2323404152","title":"方达控股公布2022年全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2323404152","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2323404152?lang=zh_CN&edition=full","pubTime":"2023-03-29 13:19","pubTimestamp":1680067140,"startTime":"0","endTime":"0","summary":"收入同比增长35.8%至250.4百万美元净利同比增长37.0%至25.9百万美元基本每股盈利和摊薄每股盈利分别同比增长40.0%和41.4%至0.0126美元和0.0123美元在手订单同比增长41.4%至341.8百万美元 香港2023年3月29日 /美通社/ -- 提供一体化、科学驱动的研究、分析和开发服务，在北美和中国同时运营业务的合同研究机构，方达控股公司，今日公布其截至2022年12月31日止年度之经审核全年业绩。2022年中国业务收入中，来自创新药开发项目的贡献超过70%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4055575_ZH55575_1","is_publish_highlight":false},{"id":"2323293182","title":"美银证券：将BioNTech SE(BNTX.O)目标价从239美元下调至194美元 维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2323293182","media":"老虎证券","top":-1,"share":"https://www.laohu8.com/m/news/2323293182?lang=zh_CN&edition=full","pubTime":"2023-03-29 00:25","pubTimestamp":1680020712,"startTime":"0","endTime":"0","summary":"【美银证券：将BioNTech SE(BNTX.O)目标价从239美元下调至194美元 维持买入评级】美港电讯APP 3月29日讯，美银证券将BioNTech的目标价从239美元下调至194美元，并保持买入评级，此前该公司公布了22财年业绩，并提供了低于预期的23财年新冠相关收入指引。随着该公司将重点从新冠相关业务转移，并继续扩大肿瘤和ID产品系列，美银仍将关注其2023年肿瘤产品线的几项数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230329004700841f6a5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230329004700841f6a5f&s=b","is_publish_highlight":false},{"id":"2322250664","title":"大摩：新冠疫苗销售额指引不及预期 下调BioNTech(BNTX.US)目标价至150美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322250664","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2322250664?lang=zh_CN&edition=full","pubTime":"2023-03-28 20:19","pubTimestamp":1680005970,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利分析师 Matthew Harrison将BioNTech(BNTX.US)的目标价从216美元下调至150美元，并保持“与大盘持平”评级。第四季度营收超出预期，但这“不是投资者关注的焦点”，因为根据管理层的指引，2023年新冠疫苗的销售额约为50亿欧元，低于普遍预测的80亿欧元。考虑到管理层的指引和重新签订的欧盟合同，摩根士丹利下调了对新冠疫苗中期销售额的预期。摩根士丹利表示，随着新冠疫苗销售额重置，2023年的焦点可以转移到药物管道上。截至发稿，BioNTech盘前涨0.05%，报123.66美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/900624.html","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0272},{"period":"1month","weight":-0.0181},{"period":"3month","weight":-0.1731},{"period":"6month","weight":-0.363},{"period":"1year","weight":-0.3172},{"period":"ytd","weight":-0.2802}],"websiteUrl":"http://www.biontech.de","compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0488},{"period":"3month","weight":0.0587},{"period":"6month","weight":0.0516},{"period":"1year","weight":0.0252},{"period":"ytd","weight":0.1189}],"name":"BioNTech SE","description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020296},{"month":2,"riseRate":0.25,"avgChangeRate":-0.020691},{"month":3,"riseRate":0.75,"avgChangeRate":0.188527},{"month":4,"riseRate":0.25,"avgChangeRate":0.067024},{"month":5,"riseRate":0.75,"avgChangeRate":0.0559},{"month":6,"riseRate":0.75,"avgChangeRate":0.096663},{"month":7,"riseRate":1,"avgChangeRate":0.268192},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.125227},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.035971},{"month":10,"riseRate":1,"avgChangeRate":0.091493},{"month":11,"riseRate":1,"avgChangeRate":0.309414},{"month":12,"riseRate":0.25,"avgChangeRate":-0.042527}],"exchange":"NASDAQ","nameEN":"BioNTech SE","compareStock":{"symbol":"SPY","name":"标普500ETF"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.13.0","shortVersion":"4.13.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}